Form 4: Aadi Bioscience Director Emma Reeve Reports Stock Option Grant

Director Emma Reeve reports the acquisition of stock options in Aadi Bioscience, Inc.

Summary

• Emma Reeve, a director of Aadi Bioscience, Inc., filed a Form 4 on June 14, 2024.
• The report details the grant of a stock option to Reeve on June 12, 2024, allowing her to purchase 45,832 shares of common stock at an exercise price of $1.70 per share.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon Reeve's continued service to the company.
• Following the transaction, Reeve directly owns 45,832 derivative securities.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The stock option grant is a moderately positive sign, aligning director interests with shareholders, but it's a standard practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates